Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNoopur Raje, James N. Kochenderfer, Jesús G. Berdeja et al.|New England Journal of Medicine|2019Cited by 1.7k
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodríguez‐Otero, Sergio Giralt, Sikander Ailawadhi et al.|New England Journal of Medicine|2023Cited by 695
Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaBrian A. Walker, Gareth J. Morgan, Pingping Qu et al.|Blood|2018Cited by 492
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisBrian A. Walker, Gareth J. Morgan, Konstantinos Mavrommatis et al.|Leukemia|2018Cited by 452